Effectiveness of chlorthalidone/amiloride versus losartan in patients with stage I hypertension: Results from the PREVER-treatment randomized trial

Journal of Hypertension

Volumn 34, Issue 4, 2016, Pages 798-806

  Fuchs, Flávio D ^a   Scala, Luiz César N ^b   Vilela Martin, José F ^c   De Mello, Renato Bandeira ^a   Mosele, Francisca ^a   Whelton, Paul K ^d   Poli De Figueiredo, Carlos E ^e   De Alencastro, Paulo Ricardo ^a   E Silva, Ricardo Pereira ^f   Gus, Miguel ^a   Bortolotto, Luiz Aparecido ^g   Schlatter, Rosane ^a   Cesarino, Evandro José ^g   Castro, Iran ^h   Neto, José A Figueiredo ⁱ   Chaves, Hilton ^j   Steffens, André Avelino ^k   Alves, João Guilherme ^l   Brandão, Andréa Araujo ^m   De Sousa, Marcos R ⁿ   Jardim, Paulo Cesar ^o   Moreira, Leila B ^a   Franco, Roberto Silva ^p   Gomes, Marco Mota ^q   Neto, Abrahão Afiune ^r   Fuchs, Felipe Costa ^a   Filho, Dario C Sobral ^s   Nóbrega, Antônio C ^t   Nobre, Fernando ^g   Berwanger, Otávio ^q   Fuchs, Sandra C ^a   more..

^a HOSPITAL DE CLÍNICAS DE PORTO ALEGRE   (Brazil)

^b HOSPITAL UNIVERSITÁRIO JÚLIO MÜLLER   (Brazil)

^c Faculdade de Medicina   (Brazil)

^d TULANE UNIVERSITY   (United States)

^e PONTIFICAL CATHOLIC UNIVERSITY OF RIO GRANDE DO SUL   (Brazil)

^f FEDERAL UNIVERSITY OF CEARÁ   (Brazil)

^g UNIVERSITY OF SÃO PAULO   (Brazil)

^h Instituto de Cardiologia   (Brazil)

ⁱ FEDERAL UNIVERSITY OF MARANHÃO   (Brazil)

^j FEDERAL UNIVERSITY OF PERNAMBUCO   (Brazil)

^k FEDERAL UNIVERSITY OF PELOTAS   (Brazil)

^l Instituto de Medicina Integral Prof Fernando Figueira IMIP   (Brazil)

^m STATE UNIVERSITY OF RIO DE JANEIRO   (Brazil)

ⁿ FEDERAL UNIVERSITY OF MINAS GERAIS   (Brazil)

^o FEDERAL UNIVERSITY OF GOIÁS   (Brazil)

^p SÃO PAULO STATE UNIVERSITY UNESP   (Brazil)

^q Hospital do Coração   (Brazil)

^r Anis Rassi Hospital   (Brazil)

^s Hospital Universitário Procape   (Brazil)

^t HOSPITAL UNIVERSITÁRIO ANTÔNIO PEDRO   (Brazil)

more..

Author keywords

amiloride; chlorthalidone; drug treatment; hypertension; losartan

Indexed keywords

AMILORIDE; CHLORTALIDONE; CHOLESTEROL; CREATININE; GLUCOSE; GLYCOSYLATED HEMOGLOBIN; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; LOSARTAN; LOW DENSITY LIPOPROTEIN CHOLESTEROL; POTASSIUM; TRIACYLGLYCEROL; URIC ACID; ANTIHYPERTENSIVE AGENT;

ADULT; ARTICLE; CHOLESTEROL BLOOD LEVEL; CONTROLLED STUDY; CREATININE BLOOD LEVEL; DIABETES MELLITUS; DIASTOLIC BLOOD PRESSURE; DIZZINESS; DOUBLE BLIND PROCEDURE; DRUG EFFICACY; DRUG INDUCED HEADACHE; EDEMA; ELEVATED BLOOD PRESSURE; FATIGUE; FEMALE; FOLLOW UP; GASTROINTESTINAL DISEASE; GLUCOSE BLOOD LEVEL; HEART PALPITATION; HUMAN; HYPERTENSION; MAJOR CLINICAL STUDY; MALE; MENTAL DISEASE; MICROALBUMINURIA; MULTICENTER STUDY; MUSCULOSKELETAL DISEASE; POLYURIA; POTASSIUM BLOOD LEVEL; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; SKIN DISEASE; SYSTOLIC BLOOD PRESSURE; URIC ACID BLOOD LEVEL; URINARY TRACT DISEASE; AGED; BLOOD PRESSURE; DRUG EFFECTS; MIDDLE AGED;

ADULT; AGED; AMILORIDE; ANTIHYPERTENSIVE AGENTS; BLOOD PRESSURE; CHLORTHALIDONE; HUMANS; HYPERTENSION; LOSARTAN; MIDDLE AGED;

EID: 84960353486     PISSN: 02636352     EISSN: 14735598     Source Type: Journal    
DOI: 10.1097/HJH.0000000000000837     Document Type: Article

References (46)

1. Lozano R, Naghavi M, Foreman K, Lim S, Shibuya K, Aboyans V, et al. Global and regional mortality from 235 causes of death for 20 age groups in 1990 and 2010: a systematic analysis for the Global Burden of Disease Study 2010. Lancet 2012; 380:2095-2128.
2. Lim SS, Vos T, Flaxman AD, Danaei G, Shibuya K, Adair-Rohani H, et al. A comparative risk assessment of burden of disease and injury attributable to 67 risk factors and risk factor clusters in 21 regions, 1990-2010: a systematic analysis for the Global Burden of Disease Study 2010. Lancet 2012; 380:2224-2260.
3. Lewington S, Clarke R, Qizilbash N, Peto R, Collins R. Age-specific relevance of usual blood pressure to vascular mortality: a meta-Analysis of individual data for one million adults in 61 prospective studies. Lancet 2002; 360:1903-1913.
4. Kearney PM, Whelton M, Reynolds K, Muntner P, Whelton PK, He J. Global burden of hypertension: analysis of worldwide data. Lancet 2005; 365:217-223.
5. Picon RV, Fuchs FD, Moreira LB, Riegel G, Fuchs SC. Trends in prevalence of hypertension in Brazil: a systematic review with metaanalysis. PLoS One 2012; 7:e48255.
6. Picon RV, Fuchs FD, Moreira LB, Fuchs SC. Prevalence of hypertension among elderly persons in urban Brazil: a systematic review with metaanalysis. Am J Hypertens 2013; 26:541-548.
7. Law MR, Morris JK, Wald NJ. Use of blood pressure lowering drugs in the prevention of cardiovascular disease: meta-Analysis of 147 randomised trials in the context of expectations from prospective epidemiological studies. BMJ 2009; 338:b1665.
8. Turnbull F, Blood Pressure Lowering Treatment Trialists? Collaboration. Effects of different blood-pressure-lowering regimens on major cardiovascular events: results of prospectively-Designed overviews of randomised trials. Lancet 2003; 362:1527-1535.
9. The Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial (ALLHAT). Major outcomes in high-risk hypertensive patients randomized to angiotensin-converting enzyme inhibitor or calcium channel blocker vs diuretic. JAMA 2002; 288:2981-2997.
10. Brown MJ, Palmer CR, Castaigne A, de Leeuw PW, Mancia G, Rosenthal T, et al. Morbidity and mortality in patients randomised to double-blind treatment with a long-Acting calcium-channel blocker or diuretic in the InternationalNifedipine GITS study (INSIGHT). Lancet 2000; 356:366-372.
11. James PA, Oparil S, Carter BL, Cushman WC, Dennison-Himmelfarb C, Handler J, et al. 2014 evidence-based guideline for the management of high blood pressure in adults: report from the panel members appointed to the Eighth Joint National Committee (JNC 8). JAMA 2014; 311:507-520.
12. Mancia G, Fagard R, Narkiewicz K, Redon J, Zanchetti A, Böhm M, et al. 2013 ESH/ESC Guidelines for the management of arterial hypertension. J Hypertens 2013; 31:1281-1357.
13. Krause T, Lovibond K, Caulfield M, McCormack T, Williams B, Guideline Development Group. Management of hypertension: summary of NICE guidance. BMJ 2011; 343:d4891.
14. Fuchs FD. The role of angiotensin receptor blockers in the prevention of cardiovascular and renal disease: time for reassessment?. Evid Based Med 2013; 18:44-47.
15. Bangalore S, Kumar S, Wetterslev J, Messerli FH. Angiotensin receptor blockers and risk of myocardial infarction: meta-Analyses and trial sequential analyses of 147 020 patients from randomised trials. BMJ 2011; 342:d2234.
16. van Vark LC, Bertrand M, Akkerhuis KM, Brugts JJ, Fox K, Mourad JJ, et al. Angiotensin-converting enzyme inhibitors reduce mortality in hypertension: a meta-Analysis of randomized clinical trials of reninangiotensin-Aldosterone system inhibitors involving 158 998 patients. Eur Heart J 2012; 33:2088-2097.
17. Cheng J, Zhang W, Zhang X, Han F, Li X, He X, et al. Effect of angiotensin-converting enzyme inhibitors and angiotensin II receptor blockers on all-cause mortality, cardiovascular deaths, and cardiovascular events in patients with diabetes mellitus: a meta-Analysis. JAMA Intern Med 2014; 174:773-785.
18. Elgendy IY, Huo T, Chik V, Pepine CJ, Bavry AA. Efficacy and safety of angiotensin receptor blockers in older patients: a meta-Analysis of randomized trials. Am J Hypertens 2015; 28:576-585.
19. Law M, Wald N, Morris J. Lowering blood pressure to prevent myocardial infarction and stroke: a new preventive strategy. Health Technol Assess 2003; 7:1-94.
20. Fuchs FD, Fuchs SC, Moreira LB, Gus M, Nóbrega AC, Poli-De-Figueiredo CE, et al. A comparison between diuretics and angiotensinreceptor blocker agents in patients with stage I hypertension (PREVER-Treatment trial): study protocol for a randomized doubleblind controlled trial. Trials 2011; 12:53.
21. Fuchs FD. Diuretics: still essential drugs for the management of hypertension. Expert Rev Cardiovasc Ther 2009; 7:591-598.
22. Guerrero P, Fuchs FD, Moreira LM, Martins VM, Bertoluci C, Fuchs SC, Gus M. Blood pressure-lowering efficacy of amiloride versus enalapril as add-on drugs in patients with uncontrolled blood pressure receiving hydrochlorothiazide. Clin Exp Hypertens 2008; 30:553-564.
23. Sokolow M, Lyon TP. The ventricular complex in left ventricular hypertrophy as obtained by unipolar precordial and limb leads. Am Heart J 1949; 37:161-186.
24. Okin PM, Roman MI, Devereux BB, Borer JS, Kiigtieid P. Electrocardiographic diagnosis of left ventricular hypertrophy by the timevoltage integral of the QRS. J Am Coll Cardiol 1994; 23:133-140.
25. Lewis EJ, Hunsicker LG, Clarke WR, Berl T, Pohl MA, Lewis JB, et al., Collaborative Study Group. Renoprotective effect of the angiotensinreceptor antagonist irbesartan in patients with nephropathy due type diabetes. N Engl J Med 2001; 345:851-860.
26. Parving HH, Lehnert H, Brochner-Mortensen J, Gomis R, Andersen S, Arner P, et al. The effect of irbesartan on the development of diabetic nephropathy in patients with type 2 diabetes. N Engl J Med 2001; 345:870-878.
27. Brenner BM, Cooper ME, Zeeuw D, Keane WF, Mitch WE, Parving HH, et al. Effects of losartan on renal and cardiovascular outcomes in patients with type 2 diabetes and nephropathy. N Engl J Med 2001; 345:861-869.
28. Dahlöf B, Devereux RB, Kjeldsen SE, Julius S, Beevers G, de Faire U, et al., for the LIFE study group. Cardiovascularmorbidity andmortality in the losartan intervention for endpoint reduction in hypertension study (LIFE): a randomised trial against atenolol. Lancet 2002; 359:995-1003.
29. Fuchs FD. Losartan for cardiovascular disease in patients with and without diabetes in the LIFE study. Lancet 2002; 359:2203.
30. MRC Working Party. Medical Research Council trial of treatment of hypertension in older adults. BMJ 1992; 304:405-412.
31. Julius S, Kjeldsen SE, Weber M, Brunner HR, Ekman S, Hansson L, et al., VALUE trial group. Outcomes in hypertensive patients at high cardiovascular risk treated with regimens based on valsartan or amlodipine: the VALUE randomised trial. Lancet 2004; 363:2022-2231.
32. Weber MA, Julius S, Kjeldsen SE, Brunner HR, Ekman S, Hansson L, et al. Blood pressure dependent and independent effects of antihypertensive treatment on clinical events in the VALUE trial. Lancet 2004; 363:2049-2051.
33. Lithell H, Hansson L, Skoog I, Elmfeldt D, Hofman A, Olofsson B, et al. The Study on Cognition and Prognosis in the Elderly (SCOPE): principal results of a randomized double-blind intervention trial. J Hypertens 2003; 21:875-886.
34. Yusuf S, Teo K, Anderson C, Pogue J, Dyal L, Copland I, et al., TRANSCEND Investigators. Effects of the angiotensin-receptor blocker telmisartan on cardiovascular events in high-risk patients intolerant to angiotensin-converting enzyme inhibitors: a randomized controlled trial. Lancet 2008; 372:1174-1183.
35. Yusuf S, Diener HC, Sacco RL, Cotton D, Ounpuu S, Lawton WA, et al., PRoFESS Study Group. Telmisartan to prevent recurrent stroke and cardiovascular events. N Engl J Med 2008; 359:1225-1237.
36. McMurray JJ, Holman RR, Haffner SM, Bethel MA, Holzhauer B, Hua TA, et al., NAVIGATOR Study Group. Effect of valsartan on the incidence of diabetes and cardiovascular events. N Engl J Med 2010; 362:1477-1490.
37. Yusuf S, Healey JS, Pogue J, Chrolavicius S, Flather M, Hart RG, et al., ACTIVE I Investigators. Irbesartan in patients with atrial fibrillation. N Engl J Med 2011; 364:928-938.
38. Haller H, Ito S, Izzo JL Jr, Januszewicz A, Katayama S, Menne J, et al., ROADMAP Trial Investigators. Olmesartan for the delay or prevention of microalbuminuria in type 2 diabetes. N Engl J Med 2011; 364:907-917.
39. Imai E, Chan JC, Ito S, Yamasaki T, Kobayashi F, Haneda M, et al., ORIENT study investigators. Effects of olmesartan on renal and cardiovascular outcomes in type 2 diabetes with overt nephropathy: a multicentre, randomised, placebo-controlled study. Diabetologia 2011; 54:2978-2986.
40. Retraction-combination treatment of angiotensin-II receptor blocker and angiotensin-converting-Enzyme inhibitor in nondiabetic renal disease (COOPERATE): a randomised controlled trial. Lancet 2009; 374:1226.
41. Retraction-valsartan in a Japanese population with hypertension and other cardiovascular disease (JIKEI HEART STUDY): a randomised, open-label, blinded endpoint morbidity-mortality study. Lancet 2013; 382:843.
42. Retraction of effects of valsartan on morbidity and mortality in uncontrolled hypertensive patients with high cardiovascular risks: KYOTO HEART Study. Eur Heart J 2013; 34:1023.
43. Emdin CA, Rahimi K, Neal B, Callender T, Perkovic V, Patel A. Blood pressure lowering in type 2 diabetes: a systematic review and metaanalysis. JAMA 2015; 313:603-615.
44. Thomopoulos C, Parati G, Zanchetti A. Effects of blood pressure lowering on outcome incidence in hypertension: 4. Effects of various classes of antihypertensive drugs-overview and meta-Analyses. J Hypertens 2015; 33:195-211.
45. SHEP Cooperative Research Group. Prevention of stroke by antihypertensive drug treatment in older persons with isolated systolic hypertension. JAMA 1991; 265:3255-3264.
46. Fuchs FD, Fuchs SC, Moreira LB, Gus M. Proof of concept in cardiovascular risk: the paradoxical findings in blood pressure and lipid abnormalities. Vasc Health Risk Manag 2012; 8:437-442.